A. Prislan
Klinični oddelek za otroško kirurgijo in intenzivno terapijo, Kirurška klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija

M. Grošelj Grenc
Klinični oddelek za otroško kirurgijo in intenzivno terapijo, Kirurška klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija

Abstract

In the beginning of 2012, new Slovenian guidelines for the treatment of newborns with suspected duct depend-ent congenital heart disease (DDCHD) requiring treatment with prostaglandin E1 (PGE1) were published (1). In this article, a clinical case of a newborn with DDCHD and measures that were performed according to the new guidelines are presented. DDCHD that require treatment with PGE1 are briey described. Finally, the main innovations in PGE1 treatment and possible treatment side effects are discussed.

Key words: congenital heart disease, newborn, prostaglandin E1, transposition of the great vessels.